These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 17659092

  • 1. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
    Monazzam A, Josephsson R, Blomqvist C, Carlsson J, Långström B, Bergström M.
    Breast Cancer Res; 2007; 9(4):R45. PubMed ID: 17659092
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, Langström B, Bergström M.
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [Abstract] [Full Text] [Related]

  • 3. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
    Bergstrom M, Monazzam A, Razifar P, Ide S, Josephsson R, Langstrom B.
    J Nucl Med; 2008 Jul; 49(7):1204-10. PubMed ID: 18552146
    [Abstract] [Full Text] [Related]

  • 4. Role of intercellular communications in breast cancer multicellular tumor spheroids after chemotherapy.
    Oktem G, Bilir A, Ayla S, Yavasoglu A, Goksel G, Saydam G, Uysal A.
    Oncol Res; 2006 Jul; 16(5):225-33. PubMed ID: 17294803
    [Abstract] [Full Text] [Related]

  • 5. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
    Kelly CJ, Hussien K, Muschel RJ.
    Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
    [Abstract] [Full Text] [Related]

  • 6. Multicellular tumour spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring.
    Monazzam A, Razifar P, Simonsson M, Qvarnström F, Josephsson R, Blomqvist C, Långström B, Bergström M.
    Cancer Cell Int; 2006 Mar 23; 6():6. PubMed ID: 16556298
    [Abstract] [Full Text] [Related]

  • 7. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
    Prados J, Melguizo C, Rama AR, Ortiz R, Segura A, Boulaiz H, Vélez C, Caba O, Ramos JL, Aránega A.
    Cancer Chemother Pharmacol; 2010 May 23; 66(1):69-78. PubMed ID: 19771430
    [Abstract] [Full Text] [Related]

  • 8. 3'-Deoxy-3'-[(18)F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment.
    Dittmann H, Jusufoska A, Dohmen BM, Smyczek-Gargya B, Fersis N, Pritzkow M, Kehlbach R, Vonthein R, Machulla HJ, Bares R.
    Nucl Med Biol; 2009 Feb 23; 36(2):163-9. PubMed ID: 19217528
    [Abstract] [Full Text] [Related]

  • 9. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
    Contractor KB, Kenny LM, Stebbing J, Challapalli A, Al-Nahhas A, Palmieri C, Shousha S, Lewis JS, Hogben K, De Nguyen Q, Coombes RC, Aboagye EO.
    Nucl Med Commun; 2011 Nov 23; 32(11):997-1004. PubMed ID: 21862943
    [Abstract] [Full Text] [Related]

  • 10. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, Galldiks N, Klein JC, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss WD.
    J Nucl Med; 2005 Dec 23; 46(12):1948-58. PubMed ID: 16330557
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
    Fushiki H, Miyoshi S, Noda A, Murakami Y, Sasaki H, Jitsuoka M, Mitsuoka K, Matsunari I, Nishimura S.
    Anticancer Res; 2013 Nov 23; 33(11):4741-9. PubMed ID: 24222108
    [Abstract] [Full Text] [Related]

  • 15. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH, Jensen MM, Kristensen LK, Dahlman A, Fröhlich C, Jacobsen HJ, Poulsen TT, Lantto J, Horak ID, Kragh M, Kjaer A.
    Oncotarget; 2015 Nov 10; 6(35):37486-99. PubMed ID: 26460961
    [Abstract] [Full Text] [Related]

  • 16. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
    Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO.
    Eur J Nucl Med Mol Imaging; 2007 Sep 10; 34(9):1339-47. PubMed ID: 17333178
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
    Jung SY, Kim SK, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Park IH, Lee KS, Shin KH, Lee S, Kim SW, Kang HS, Ro J.
    Ann Surg Oncol; 2010 Jan 10; 17(1):247-53. PubMed ID: 19777177
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.
    Breast Cancer; 2013 Apr 10; 20(2):167-73. PubMed ID: 22311581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.